# Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection

> **NCT03158077** · — · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 467 (actual)

## Conditions studied

- HIV Infections

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03158077
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-15
- **Primary completion:** 2017-04-20
- **Final completion:** 2017-04-20
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2017-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158077, "Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03158077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*